Effective Control of Polymyalgia Rheumatica With Tocilizumab

Despite their disadvantages, glucocorticoids (GCs) remain a mainstay of therapy for polymyalgia rheumatica (PMR). Second-line antirheumatic and immune-modulatory drugs are not infrequently required because of disease relapses during GC tapering and GC adverse effects. Therapy with methotrexate or with an anti–tumor necrosis factor drug showed modest efficacy in this situation. Tocilizumab (TCZ) is an anti–interleukin 6 receptor antibody that is...